1. Introduction and Indications

Tysabri (natalizumab) is a humanized monoclonal antibody approved by the FDA for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is also indicated for adults with moderate-to-severe Crohn’s disease who have not responded adequately to conventional therapies or anti-TNF agents.

Clinical Relevance:
Natalizumab represents a significant advancement in the management of both neurological and gastrointestinal diseases due to its unique mechanism targeting lymphocyte trafficking, which plays a pivotal role in inflammatory pathology.

2. Mechanism of Action

Natalizumab binds with high affinity to the α4 subunit (specifically α4b1 and α4b7) found on the surface of most leukocytes (except neutrophils), blocking their interaction with VCAM-1 expressed on endothelial cells. This prevents lymphocyte migration into the central nervous system (CNS) and gut mucosa, thereby reducing inflammatory cell infiltration and subsequent tissue damage.

Clinical Insight:
This mechanism is particularly relevant in MS (where CNS inflammation drives demyelination) and Crohn’s disease (where gut inflammation leads to chronic diarrhea and abdominal pain). Natalizumab’s specificity for α4 integrins minimizes broad immunosuppression, but also confers unique risks such as PML.

3. Dosage and Administration

Multiple Sclerosis:

• Route: IV infusion
• Dose: 300 mg per administration
• Frequency: Every 4 weeks
• Administration: Administered intravenously over approximately 1 hour; not to be given as a bolus or push.

Crohn’s Disease:

• Route: IV infusion
• Dose: 300 mg every 4 weeks
• Patient Selection: Used when conventional therapies (e.g., anti-TNF agents) have failed or are not tolerated.

Pharmacist Notes:

• Ensure proper storage and preparation per manufacturer’s instructions.
• Monitor for infusion reactions during and after administration.
• Document all prior MS/Crohn’s disease treatments and responses.

4. Adverse Effects & Safety Considerations

Serious Adverse Events:

• Progressive Multifocal Leukoencephalopathy (PML):
  • Caused by JC virus reactivation; fatal or causes permanent neurological disability.
  • Risk factors include prior immunosuppressant use, prolonged natalizumab exposure, and prior PML.
  • Monitoring: Baseline and periodic JCV antibody testing recommended in high-risk patients.
• Serious Infections:
  • Increased risk of opportunistic infections (e.g., fungal, viral).
  • Monitor for fever, chills, or signs of systemic infection.
• Infusion Reactions:
  • May occur during administration; manage with slowing infusion rate and supportive care.

Other Notable Effects:

• Dizziness, nausea, pruritus, and rare anaphylaxis.
• Potential for serious CNS infections (meningitis, encephalitis).

5. Drug Interactions

Natalizumab’s immunosuppressive action may be potentiated or complicated by concomitant medications:

• Immunosuppressants: Azathioprine, cyclosporine, 6-MP, methotrexate, fingolimod, and other biologics (e.g., anti-TNF agents) increase infection risk.
• Corticosteroids: Long-term use may alter immune response.

Pharmacist Action:

• Review all concomitant medications for immunosuppressive effects or infection risk.
• Coordinate with prescriber to adjust therapy as needed and monitor closely.

6. Precautions & Contraindications

• Absolute Contraindications:
  • History of PML or JC virus infection.
  • Severe hypersensitivity to natalizumab.
• Relative Contraindications:
  • Active infections, recent fever, or unexplained illness.
  • Concurrent use with other immunosuppressants (unless specifically indicated and monitored).
• Pregnancy/Lactation:
  • Pregnancy: Data limited; potential fetal immunologic/hematologic effects in animal models. Use only if benefit justifies risk.
  • Lactation: Natalizumab present in breast milk; theoretical risk to infant.

7. Storage and Stability

• Store refrigerated at 2–8°C (36–46°F).
• Do not freeze.
• Discard after expiration or if solution appears discolored/particulate.

8. Summary for Clinical Practice

Natalizumab is a powerful disease-modifying therapy with significant efficacy in MS and Crohn’s disease, but its use requires careful patient selection, vigilant monitoring for serious adverse events (especially PML), and awareness of potential drug interactions. Pharmacists play a crucial role in ensuring safe administration, counseling patients on risks, and coordinating multidisciplinary care.

References:

• FDA Prescribing Information for Tysabri (natalizumab)
• National Multiple Sclerosis Society Guidelines
• American Gastroenterological Association Recommendations for Crohn’s Disease
• UpToDate: Natalizumab in Multiple Sclerosis and Crohn’s Disease
• ClinicalTrials.gov: PML risk factors and monitoring protocols

Key Takeaway:
Natalizumab is a targeted therapy with unique risks and benefits. Pharmacists should be familiar with its mechanism, contraindications, adverse effect profile, and the importance of infection surveillance to optimize patient outcomes.